---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059089"
form_type: "8-K"
ticker: null
cik: "0001178879"
company_name: "AMICUS THERAPEUTICS, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:57:28.816763+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Amicus Q1 revenue $110.4M (+28% YoY); raises Galafold growth guidance to 13-17%

## Summary
- Total revenue $110.4M, up 28% YoY; Galafold net sales $99.4M (+15% YoY).
- Pombiliti+Opfolda net sales $11.0M, up 30% from Q4 2023; over 155 patients on/commercial treatment.
- GAAP net loss $48.4M ($0.16/sh); non-GAAP net loss $4.6M ($0.02/sh), improved from $16.8M loss in Q1 2023.
- Raises full-year Galafold revenue growth guidance to 13-17% (from 11-16%); total revenue growth guided 25-30%.
- Cash and securities $239.6M; reiterates full-year non-GAAP profitability projected in 2024.

## SEC filing metadata
- accession: 0001104659-24-059089
- form_type: 8-K
- cik: 0001178879
- company_name: AMICUS THERAPEUTICS, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/0001104659-24-059089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/tm2413954d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059089
- JSON: https://secwatch.observer/filing/0001104659-24-059089.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059089.txt

## Key facts
- Earnings Releases
  AMICUS THERAPEUTICS, INC. updated its the first quarter ended March 31, 2024 guidance (raised).
  - Period: the first quarter ended March 31, 2024
  - Guidance: raised
  - Result: reported results
  source text: On May 9, 2024, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178879/000110465924059089/0001104659-24-059089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.